442 articles in this topic
Wave Life Sciences shares early trial data on an RNA editing treatment for alpha-1 antitrypsin deficiency, targeting monthly dosing.
GLP-1 use surged 140% as bariatric surgery dropped 34%. New findings span creatine for menopause, osteoporosis risk, and obesity trend reversals.
A Stanford trial finds combining buprenorphine with ketamine nearly doubles the reduction in suicidal ideation scores over 31 days.
New findings challenge omega-3 supplementation for brain health, while sleep and genetics shape Alzheimer's risk in women.
A second wave of RAS-targeting therapies is reshaping cancer treatment, with implications for longevity through better tumor control.
Scientists boosted a protein that dampens chronic inflammation, and older mice grew stronger, more energetic, and had healthier bones.
A topical senolytic drug cleared aging 'zombie' cells from old skin, helping aged mice heal wounds 43% more completely by day 24.
A new Cas12a2-based system identifies cancerous or virus-infected cells by their RNA and destroys them — tested across multiple human cancer lines.
JCR Pharmaceuticals shows its JUST-AAV platform can cross the blood-brain barrier, extending survival in neurological disease mouse models.
Insilico Medicine's AI-generated TNIK inhibitor enters Phase 1 trials for pulmonary fibrosis, signaling a new era in drug discovery.
AstraZeneca's BAXFENDY cuts systolic blood pressure by nearly 10 mmHg beyond placebo in adults whose BP wasn't controlled by other drugs.
A Phase 1b trial shows a daily probiotic capsule may restore immunotherapy response in advanced melanoma patients who had stopped responding.
